Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor

Movement Disorders

Volumn 18, Issue 11, 2003, Pages 1324-1331

  Navan, Prithiva ^a   Findley, Leslie J ^b   Jeffs, Jim A R ^c   Pearce, Ronald K B ^a   Bain, Peter G ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b Havering Hospital NHS Trust   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Dopamine receptors; Parkinson's disease; Pergolide; Pramipexole; Randomized controlled trial; Tremor

Indexed keywords

AMANTADINE; DOMPERIDONE; LEVODOPA; ORPHENADRINE; PERGOLIDE; PLACEBO; PRAMIPEXOLE; PROPRANOLOL; SELEGILINE; TRIHEXYPHENIDYL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVARIANCE; DISEASE DURATION; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; HALLUCINATION; HEADACHE; HUMAN; MALE; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SLEEP DISORDER; TREATMENT OUTCOME; TREMOR;

AGED; AGED, 80 AND OVER; BENZOTHIAZOLES; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PERGOLIDE; SEVERITY OF ILLNESS INDEX; THIAZOLES; TREMOR;

EID: 1342326289     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10538     Document Type: Article

References (25)

1. Deuschl G, Bain P, Brin M, and an Ad Hoc Scientific Committee. Consensus statement of the Movement Disorder Society on tremor. Mov Disord 1998;13(Suppl. 3):2-23.
2. Bain PG. The management of tremor. J Neurol Neurosurg Psychiatry 2002;72(Suppl. 1):i3-i9.
3. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from cumulative literature. Mov Disord 2001;16:448-458.
4. Schrag A, Keens J, Warner J. Ropinirole for the treatment of tremor in early Parkinson's disease. Eur J Neurol 2002;9:253-257.
5. Kunig G, Pogarell O, Moller JC, Delf M, Oertel W. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease. Clin Neuropharmacol 1999;5:301-305.
6. Pogarell O, Gasser T, van Hilten JJ, Spieker S, Pollentier S, Meier D, Oertel WH. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 2002;72:713-720.
7. Navan P, Findley LJ, Jeffs J, Pearce RKB, Bain PG. A double-blind single dose cross-over study of the effects of pramipexole, pergolide and placebo on rest-tremor and UPDRS III in Parkinson's disease. Mov Disord 2002 (in press).
8. 2 dopamine receptors important for optimal motor functioning in Parkinson's disease? Eur J Neurol 1997;4:3-11.
9. Mierau J, Schneider FJ, Ensinger H, Chio CL, Lajiness ME, Huff RM. Pramipexole binding and activation of cloned and expressed dopamine D2, D3, and D4 receptors. Eur J Pharmacol 1995;290: 29-36.
10. Piercey MF, Camacho-Ochoa M, Smith MW. Functional roles for dopamine-receptor subtypes. Clin Neuropharmacol 1995; 18(Suppl.):34-42.
11. Piercey MF, Hoffmann WE, Smith MW, Hyslop DK. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol 1996;312:35-44.
12. Le Witt PA. Pharmacology of dopaminergic agonists for Parkinson's disease. In: Le Witt PA, Oertel W, editors. Parkinson's disease the treatment options. London: Martin-Dunitz; 1999. p 159-186.
13. Celance (pergolide mesylate) and Mirapexin (pramipexole) data sheets. In: ABPI Compendium of Data Sheets and Summaries of Product Characteristics. London: Datapharm Publications; 1999-2000. p 734 and also ABPI website: http://emc.vhn.net.
14. Silverdale MA, Milan MJ, Newman-Tancredi A, Crossman AR, Brotchie JM. Antiparkinsonian actions of the selective dopamine D3 receptor antagonist S33084. J Neurol Neurosurg Psychiatry 2002;73:215.
15. Navan P, Findley LJ, Pearce RKB, Bain PG. A study of the relative reliabilities of different ways of measuring the magnitude of parkinsonian tremors. Parkinsonism Relat Disord 2001;7(Suppl.): S124.
16. Bain PG, Findley LJ, Atchison P, Behari M, Vidailhet M, Gresty M, Rothwell J, Thompson PD, Marsden CD. Assessing tremor severity. J Neurol Neurosurg Psychiatry 1993;56:868-873.
17. Fahn S, Elton RL, and members of the UPDRS development committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, editors. Recent developments in Parkinson's disease. Vol. 2. Florham Park, NJ: Macmillan Health Care Information; 1987. p 153-164.
18. Wade DT. Measures of focal disability. In: Measurement in neurological rehabilitation. Oxford: Oxford University Press; 1992.
19. Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev 1988;8:77-100.
20. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1993;17:361-370.
21. Euroqol Group. Euroqol: a new facility for the measurement of health related quality of life. Health Policy 1990;16:199-208.
22. Matsumoto JY, Dodick DW, Stevens LN, Newman RC, Caskey PE, Fjerstad W. Three-dimensional measurement of essential tremor. Mov Disord 1999;14:288-294.
23. Solida A, Ghika J, Vingerhoets F. Acute dopaminergic challenge tests to assess postural/kinetic tremor of different origin: a case report. J Neurol Neurosurg Psychiatry 2002;73:206-207.
24. Kompoliti K, Adler CH, Raman R, Pincus JH, Leibowitz MT, Ferry JJ, Blasucci L, Caviness JN, Leurgans S, Chase WM, Yones LC, Tan E, Carvey P, Goetz CG. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology 2002;58:1418-1422.
25. Navan P, Bain PG. Long-term tolerability of high dose ergoline-derived dopamine agonist therapy for the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 2002;72:602-603.